BioNTech SE (BNTX)
NASDAQ: BNTX · Real-Time Price · USD
98.15
-1.11 (-1.12%)
At close: Sep 17, 2025, 4:00 PM EDT
98.25
+0.10 (0.10%)
After-hours: Sep 17, 2025, 7:21 PM EDT
BioNTech SE Employees
BioNTech SE had 6,772 employees as of December 31, 2024. The number of employees increased by 639 or 10.42% compared to the previous year.
Employees
6,772
Change (1Y)
639
Growth (1Y)
10.42%
Revenue / Employee
$499,171
Profits / Employee
-$59,795
Market Cap
23.60B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6,772 | 639 | 10.42% |
| Dec 31, 2023 | 6,133 | 1,603 | 35.39% |
| Dec 31, 2022 | 4,530 | 1,448 | 46.98% |
| Dec 31, 2021 | 3,082 | 1,141 | 58.78% |
| Dec 31, 2020 | 1,941 | 631 | 48.17% |
| Dec 31, 2019 | 1,310 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BNTX News
- 5 days ago - COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says - Market Watch
- 9 days ago - BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy - Benzinga
- 9 days ago - BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial - Reuters
- 9 days ago - First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity - GlobeNewsWire
- 9 days ago - Pfizer, partner BioNTech say updated COVID shot shows better immune response - Reuters
- 9 days ago - Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula - Business Wire
- 12 days ago - BioNTech, Duality score initial trial win with breast cancer precision drug - Reuters
- 20 days ago - mRNA Biotechs - Long-Term Value Risks Abound - Seeking Alpha